Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: A randomised, placebo-controlled, crossover phase 2a study

Disease Areas:
Cough
Device Types:
VitaloJAK

This Phase IIa, double-blind crossover study evaluated the efficacy, safety, and tolerability of eliapixant in 37 adult patients with refractory chronic cough attending specialist centers in the United Kingdom. The primary efficacy endpoint was change in cough frequency assessed over 24 hours using the Vitalograph VitaloJAK device.

chevron_right View Article

Contact Us